Abstract
Congenital and acquired thrombophilic states pose a risk of thromboembolic disease and pregnancy-specific disorders. Treatment with heparin can significantly reduce these risks.
Defined criteria indicate laboratory tests for thrombophilia. The use of prophylactic or therapeutic doses of heparin result from a particular clinical situation and the level of individual risk.
A comprehensive approach includes ongoing monitoring of the fetus using ultrasonography and cardiotocography. Indicated anticoagulant treatment must be applied in the course of 6-8 weeks after birth.
From the observed prothrombotic state should be inferred measures restricting other potential risks.